Skip to main content
VaccineWatch
VaccinesSymptomsStatesAnalysisToolsDashboardCompare

VaccineWatch

Transparent access to VAERS data for informed decision-making. We present the data as-is, with appropriate context and disclaimers.

Explore Data

  • Vaccines
  • Symptoms
  • Manufacturers
  • States
  • Dashboard
  • Compare Tool
  • Search

Deep Dives

  • The Denominator Problem
  • Onset Timing
  • Lot Number Analysis
  • COVID Impact
  • Myocarditis
  • Death Reports
  • Interactive Tools
  • Reporting Rate Calculator
  • Signal Detection
  • All 23 Articles →

Resources

  • About
  • Methodology
  • FAQ
  • Glossary
  • Side Effects Guide
  • Vaccine Schedule
  • Vaccine Safety
  • Safety Timeline
  • Adverse Events
  • Is VAERS Reliable?
  • Myocarditis
  • Guillain-Barré
  • Allergic Reactions
  • Report an Event
  • Disclaimer
  • VAERS Official Site ↗

Sister Sites

  • OpenMedicaid
  • OpenFeds
  • OpenImmigration
  • OpenSubsidies
  • OpenSpending
  • OpenMedicare
  • OpenLobby
  • TheDataProject.ai

Data source: VAERS (Vaccine Adverse Event Reporting System)

Data through 2026 · Updated quarterly

Built by TheDataProject.ai · © 2026 VaccineWatch

Important: VAERS accepts reports of adverse events following vaccination. For any given report, there is no certainty that the reported event was caused by the vaccine. Reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. Most reports to VAERS are voluntary, which means they are subject to biases. This data cannot be used to determine if vaccines cause or contribute to adverse events.

⚠️

Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.

  1. Home
  2. Vaccines
  3. Meningococcal Conjugate (Menactra)
  4. CSF test abnormal
Meningococcal Conjugate (Menactra)×CSF test abnormal

CSF test abnormal Reports for Meningococcal Conjugate (Menactra)

#344 most reported symptom for this vaccine

43
Reports
1
Deaths
34
Hospitalizations
2.33
Mortality Rate
%
79.1
Hosp. Rate
%

CSF test abnormal and Meningococcal Conjugate (Menactra)

CSF test abnormal has been reported 43 times in association with Meningococcal Conjugate (Menactra) vaccination in VAERS. This represents 0.1% of all 36,149 reports for this vaccine.

Among these reports, 1 mentioned death (2.33%) and 34 involved hospitalization (79.1%).

CSF test abnormal is the #344 most frequently reported symptom for Meningococcal Conjugate (Menactra) out of 1843 total symptoms.

Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.

What This Means

Seeing 43 reports of CSF test abnormal after Meningococcal Conjugate (Menactra) vaccination may seem alarming, but context is critical.

The mortality rate of 2.33% warrants monitoring, though VAERS deaths represent temporal associations, not confirmed causal links.

Important Context

•Association, not causation: These reports show CSF test abnormal occurred after vaccination, not that the vaccine caused it.
•Background rates: CSF test abnormal may occur naturally at baseline rates in the population, unrelated to vaccination.
•Anyone can report: VAERS accepts reports from anyone — patients, parents, healthcare providers — without requiring medical verification.
•Denominator missing: VAERS counts reports, not rates per dose. Without knowing how many doses were given, raw counts can be misleading. Learn more →

Similarly Ranked Symptoms

Fear44 reportsNeisseria test positive44 reportsAlanine aminotransferase increased43 reportsThirst43 reports

Quick Facts

Reports:43
Deaths:1
Hospitalizations:34
% of Vaccine:0.1%
Rank:#344 of 1843

Related Pages

Meningococcal Conjugate (Menactra) OverviewCSF test abnormal (All Vaccines)Why Raw Numbers MisleadTop Symptoms Analysis

Data Source

This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.